JP2019504866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504866A5 JP2019504866A5 JP2018542763A JP2018542763A JP2019504866A5 JP 2019504866 A5 JP2019504866 A5 JP 2019504866A5 JP 2018542763 A JP2018542763 A JP 2018542763A JP 2018542763 A JP2018542763 A JP 2018542763A JP 2019504866 A5 JP2019504866 A5 JP 2019504866A5
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- pharmaceutical composition
- composition according
- derivative
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001913 cellulose Substances 0.000 claims 15
- 229920002678 cellulose Polymers 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000008186 active pharmaceutical agent Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000195493 Cryptophyta Species 0.000 claims 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004380 Cholic acid Substances 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 241001466453 Laminaria Species 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 125000005233 alkylalcohol group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229940099352 cholate Drugs 0.000 claims 1
- 229960002471 cholic acid Drugs 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- -1 etensamide Chemical compound 0.000 claims 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 1
- 229960004369 flufenamic acid Drugs 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 1
- 229960002905 tolfenamic acid Drugs 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022001035A JP2022037240A (ja) | 2016-02-12 | 2022-01-06 | 新規組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1602579.3 | 2016-02-12 | ||
| GBGB1602579.3A GB201602579D0 (en) | 2016-02-12 | 2016-02-12 | New compositions |
| PCT/GB2017/050345 WO2017137762A1 (en) | 2016-02-12 | 2017-02-10 | New compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001035A Division JP2022037240A (ja) | 2016-02-12 | 2022-01-06 | 新規組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504866A JP2019504866A (ja) | 2019-02-21 |
| JP2019504866A5 true JP2019504866A5 (enExample) | 2020-03-26 |
| JP7046000B2 JP7046000B2 (ja) | 2022-04-01 |
Family
ID=55697649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018542763A Active JP7046000B2 (ja) | 2016-02-12 | 2017-02-10 | 新規組成物 |
| JP2022001035A Withdrawn JP2022037240A (ja) | 2016-02-12 | 2022-01-06 | 新規組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001035A Withdrawn JP2022037240A (ja) | 2016-02-12 | 2022-01-06 | 新規組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11278563B2 (enExample) |
| EP (1) | EP3413873B1 (enExample) |
| JP (2) | JP7046000B2 (enExample) |
| KR (1) | KR102828449B1 (enExample) |
| AU (1) | AU2017217331B2 (enExample) |
| ES (1) | ES2971977T3 (enExample) |
| GB (1) | GB201602579D0 (enExample) |
| WO (1) | WO2017137762A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109738540A (zh) * | 2019-01-28 | 2019-05-10 | 山东鲁抗舍里乐药业有限公司 | 一种非甾体抗炎药非罗考昔含量的测定方法 |
| EP3804701A1 (de) * | 2019-10-10 | 2021-04-14 | Bayer AG | Verfahren zur herstellung einer pharmazeutischen formulierung mit kristallinen und amorphen anteilen eines wirkstoffes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0970424A (ja) | 1995-07-04 | 1997-03-18 | Takeda Chem Ind Ltd | 粒剤の製造法 |
| DK1163234T3 (da) | 1999-03-24 | 2006-02-27 | Scherer Technologies Inc R P | Farmaceutiske formuleringer med forbedret vandoplöselighed |
| EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
| DK1663168T3 (da) * | 2003-09-08 | 2009-06-08 | Mcneil Ab | Nikotinformuleringer og anvendelse deraf |
| CN101102753A (zh) | 2004-12-09 | 2008-01-09 | 拉格纳·Ek | 包含低结晶度纤维素的药物制剂 |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| EP2135601A1 (en) | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
-
2016
- 2016-02-12 GB GBGB1602579.3A patent/GB201602579D0/en not_active Ceased
-
2017
- 2017-02-10 AU AU2017217331A patent/AU2017217331B2/en active Active
- 2017-02-10 KR KR1020187026291A patent/KR102828449B1/ko active Active
- 2017-02-10 WO PCT/GB2017/050345 patent/WO2017137762A1/en not_active Ceased
- 2017-02-10 JP JP2018542763A patent/JP7046000B2/ja active Active
- 2017-02-10 US US16/077,044 patent/US11278563B2/en active Active
- 2017-02-10 EP EP17710030.2A patent/EP3413873B1/en active Active
- 2017-02-10 ES ES17710030T patent/ES2971977T3/es active Active
-
2022
- 2022-01-06 JP JP2022001035A patent/JP2022037240A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105175473B (zh) | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 | |
| WO1998008966A1 (en) | Loxoprofen-containing preparation for external use | |
| TWI488644B (zh) | Preparation method of adhesive preparation, adhesive agent and packaging body | |
| JP2012515754A5 (enExample) | ||
| JPS60155111A (ja) | 安定なケトプロフェン含有外用経皮製剤 | |
| JPH02288827A (ja) | 乾癬疾患を抑制するための薬剤及びその製法 | |
| RU2430717C2 (ru) | Содержащий тритерпен агент образования олеогеля, содержащий тритерпен олеогель, и способ получения содержащего тритерпен олеогеля | |
| CN103054793A (zh) | 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法 | |
| JP2009511577A5 (enExample) | ||
| JP2022037240A (ja) | 新規組成物 | |
| CN110141653B (zh) | 一种含总姜酚的组合物及其制备方法 | |
| CN102079767B (zh) | 卤甲松单水合物的制备方法 | |
| CN106539804A (zh) | 一种用于缓解骨关节炎疼痛的分子中药霜剂及其制备方法 | |
| CN102526080B (zh) | 一种含有水杨酸甲酯乳糖苷的药物组合物、片剂及其制备方法 | |
| CN104761449B (zh) | 一种解热、镇痛、抗炎药物化合物及其制备方法 | |
| CN103877084B (zh) | 一种治疗肛周溃疡的外用药物 | |
| CN105998233B (zh) | 马甲子或其提取物在制备治疗过敏性皮炎的药物中的用途 | |
| CN104784659A (zh) | 一种治疗高血脂的中药片剂及其制备方法 | |
| CN105669696B (zh) | 一种盐酸普拉格雷化合物 | |
| CN108478540A (zh) | 一种雷公藤缓释微胶囊的制备方法 | |
| CN121421951A (zh) | 一种复方双花外用凝胶剂及其制备方法 | |
| CN104478784A (zh) | 一种西洛多辛草酸盐的晶型及其制备方法 | |
| CN105709236B (zh) | 一种促进吴茱萸碱透皮吸收的组合物及巴布剂 | |
| BR102016030713A2 (pt) | Sistemas sólidos dispersos dos triterpenos alfa- amirina, beta-amirina e a mistura natural alfa, beta amirina e suas aplicações | |
| JPH08295627A (ja) | 薬剤組成物 |